TriSalus Preclinical Data Shows PEDD Boosts Nelitolimod Delivery and Immune Response in Liver Tumors
Event summary
- TriSalus published preclinical research in Frontiers in Oncology demonstrating enhanced delivery and immune activation of nelitolimod using Pressure-Enabled Drug Delivery (PEDD) in liver tumor models.
- PEDD administration via the TriNav Infusion System resulted in significantly greater intratumoral distribution of nelitolimod compared to conventional delivery methods.
- Treatment with PEDD and nelitolimod reduced immunosuppressive myeloid-derived suppressor cells (MDSCs) and increased cytotoxic CD8+ T cell infiltration in the tumor microenvironment.
- In a murine liver metastasis model, nelitolimod delivered via PEDD significantly reduced tumor growth compared to systemic administration.
The big picture
TriSalus's data reinforces the growing trend of combining novel drug delivery technologies with immunotherapies to improve outcomes in solid tumors. The findings support the broader potential of PEDD as a platform capable of enhancing intratumoral delivery of multiple therapeutic modalities, addressing a critical challenge in oncology treatment. The company's strategy of integrating PEDD with locoregional immunotherapy approaches positions it at the intersection of medical device innovation and immuno-oncology.
What we're watching
- Clinical Translation
- Whether the preclinical findings will translate into clinical efficacy in human trials of nelitolimod delivered via PEDD.
- Partnership Strategy
- The pace at which TriSalus will explore and secure partnerships for the development of nelitolimod and PEDD technology.
- Competitive Positioning
- How TriSalus's PEDD platform will differentiate itself in the crowded field of oncology drug delivery and immunotherapy.
Related topics